Clinical Trial Update: Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting completion of the study evaluating ONO-4538 (nivolumab) in unresectable advanced or recurrent gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Gastric Cancer | Phase 3 | Status: COMPLETED